CARB-X is backing NeoTest, a Center for Global Development program designed to bridge neonatal sepsis diagnostics from development to market. Reporting said the initiative includes a proposed ten-year, $60 million market-shaping facility combining “push” grants and “pull” advanced market commitments. NeoTest will support development of assays that can be adapted for newborns at or near point of care, including a target product profile calling for tests to rule in or out sepsis for initial clinical decision-making. The proposal outlines milestone payments, implementation support to unlock demand, and a per-test top-up for qualifying tests. CARB-X and CGD identified and reviewed dozens of firms working on neonatal sepsis tests, aiming to create incentives aligned with low-resource deployment needs. If executed, the model could lower the time-to-adoption risk that often slows adoption of diagnostics in neonatal care settings.